ALLERGAN AUSTRALIA PTY LIMITED

Doudna and Charpentier's lawyers seek to revoke their European CRISPR–Cas9 patents after an unfavorable EPO opinion, citing procedural strategy rather than conceding patent invalidity, while maintaining broader patent protection in Europe and the US.

Chapters cover methodology, executive summary, market variables, segmentation by disease, molecule, biological target, mechanism, and region, and competitive landscape.

FDA approves Allergan Aesthetics' Botox Cosmetic for treating moderate to severe vertical platysma bands, offering a nonsurgical option for neck band improvement. Phase III studies showed significant improvement and patient satisfaction. Potential adverse effects include excessive weakness and dysphagia.

Alembic Pharmaceuticals received USFDA approval for its Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg, therapeutically equivalent to Allergan's Dilacor XR. Indicated for hypertension and chronic stable angina, the market size is estimated at USD 28.2 million by June 2024.

Alembic Pharmaceuticals receives USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules (120 mg, 180 mg, 240 mg), therapeutically equivalent to Allergan's Dilacor XR, used for hypertension and chronic stable angina. The US market size for these capsules is $28.2 million by June 2024, boosting Alembic's total ANDA approvals to 217, with 190 final.

Tolerance Bio, a biopharmaceutical company focused on thymus function manipulation, closed a $17.2 million seed financing round. The company aims to develop iPSC-based cell therapies and pharmacological treatments for immune-mediated diseases, including cancer and autoimmunity. The technologies were developed by a team with extensive experience in biopharma, including former executives from Provention Bio and Celimmune.

Horizon Surgical Systems, a micro-robotics company, closed a $30 million Series A round to advance its AI-enabled Polaris platform for ophthalmologic procedures. The funding will support in-human studies and team expansion, aiming to enhance surgical precision and accessibility. ExSight Ventures and a major corporate investor led the financing, with key figures joining Horizon's board.

The FTC's 2023 revised merger guidelines impact pharmaceutical industries with stricter HHI and market share requirements, emphasizing direct evidence of market dominance and ecosystem competition. The FTC scrutinizes pharmaceutical mergers for market concentration, innovation, and entry barriers, with ongoing investigations into Novo Nordisk/Catalent and AbbVie/Cerevel mergers. The EC investigates Zoetis for potential abuse of dominance post-merger, and the FTC challenges fraudulent patents to prevent market monopolization. Pharmaceutical companies are increasingly merging with biotech firms to offset patent expirations and enhance product portfolios.

The 'Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type' report outlines market players addressing antimicrobial resistance, including drug manufacturers, biotech companies, and regulatory bodies. It highlights the role of diagnostics in combating AMR and identifies 6 key market opportunities. The report provides five-year market forecasts and profiles over 100 biotech companies.

Competition authorities are expanding their review of pharmaceutical deals, focusing on whether existing tools for identifying and remedying competition issues are sufficient. The Multilateral Pharmaceutical Merger Task Force explores new enforcement approaches, considering factors like innovation effects, conglomerate effects, and coordinated effects. Authorities in regions like the EU, US, and APAC assess theories of harm, market definitions, and legal standards, with remedies often involving divestitures to ensure market competition.